Goodwin advised Abingworth on the final closing of its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. ABV VII exceeded its target of $300…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
